Table 3.
Network meta-analysis for the safety of CMIs combined with RT or CCRT for cervical cancer.
| GRR | |||||||
|---|---|---|---|---|---|---|---|
| LRR | RT | – | 2.93 (0.29, 29.53) | – | 0.33 (0.01, 17.66) | – | |
| 0.63 (0.15, 2.62) | RT + AD | – | – | – | – | ||
| 0.10 (0.00, 0.48) | 0.17 (0.02, 1.30) | RT + FFKS | – | 0.11 (0.00, 4.27) | – | ||
| 0.42 (0.07, 2.62) | 0.66 (0.06, 6.86) | 3.98 (0.36, 44.13) | RT + KA | – | – | ||
| 0.14 (0.04, 1.56) | 0.38 (0.04, 4.02) | 2.32 (0.21, 25.83) | 0.58 (0.04, 8.08) | RT + KLT | – | ||
| 0.01 (0.00, 0.21) | 0.02 (0.00, 0.48) | 0.14 (0.01, 3.06) | 0.03 (0.00, 0.91) | 0.06 (0.00, 1.58) | RT + YDZ | ||
| RT + DDP | 0.36 (0.19, 0.70) | – | 0.46 (0.24, 0.89) | 0.20 (0.07, 0.58) | |||
| 0.31 (0.00, 254) | RT + DDP + AD | – | – | – | |||
| 0.15 (0.00, 2.52e + 06) | 0.49 (0.00, 24961) | RT + DDP + FFKS | 1.27 (0.50, 3.21) | 0.54 (0.15, 1.93) | |||
| 0.34 (0.00, 903) | 1.07, (0.00, 4055) | 2.19 (0.00, 1.21e + 07) | RT + DDP + KA | 0.43 (0.12, 1.53) | |||
| 0.12 (0.00, 61.88) | 0.37 (0.00, 269) | 0.77 (0.00, 1.73e + 06) | 0.35 (0.00, 2666) | RT + DDP + KLT | |||
| RT + DP | 0.48 (0.31, 0.75) | 0.24 (0.14, 0.42) | 0.49 (0.13, 1.78) | 0.35 (0.12, 1.03) | |||
| 0.84 (0.19, 3.76) | RT + DP + FFKS | 0.51 (0.25, 1.03) | 1.02 (0.26, 4.00) | 0.74 (0.23, 2.35) | |||
| 0.38 (0.03, 5.08) | 0.46 (0.02, 8.98) | RT + DP + KA | 2.01 (0.50, 8.11) | 1.45 (0.44, 4.80) | |||
| 0.08 (0.00, 3.55) | 0.10 (0.00, 5.59) | 0.21 (0.00, 20.50) | RT + DP + KLT | 0.72 (0.14, 3.88) | |||
| 0.38 (0.03, 5.13) | 0.45 (0.02, 9.04) | 0.98 (0.03, 38.59) | 4.65 (0.05, 457.47) | RT + DP + RSDT | |||
| RT + TP | 0.54 (0.13, 2.26) | 0.78 (0.06, 10.07) | 0.36 (0.03, 4.71) | 0.39 (0.03, 5.59) | 0.38 (0.03, 5.41) | 0.46 (0.03, 6.23) | |
| 1.40 (0.53, 3.74) | RT + TP + FFKS | 1.43 (0.08, 26.78) | 0.66 (0.03, 12.50) | 0.72 (0.04, 14.68) | 0.70 (0.03, 14.21) | 0.85 (0.04, 16.49) | |
| 0.38 (0.16, 0.90) | 0.27 (0.07, 1.00) | RT + TP + HQ | 0.46 (0.01, 17.42) | 0.50 (0.01, 20.19) | 0.49 (0.01, 19.56) | 0.60 (0.02, 22.91) | |
| 1.14 (0.48, 2.71) | 0.82 (0.22, 3.01) | 3.00 (0.89, 10.16) | RT + TP + KA | 1.09 (0.03, 44.12) | 1.06 (0.03, 42.75) | 1.29 (0.03, 50.07) | |
| 0.29 (0.09, 0.91) | 0.21 (0.05, 0.94) | 0.77 (0.18, 3.20) | 0.26 (0.06, 1.07) | RT + TP + SM | 0.97 (0.02, 41.71) | 1.19 (0.03, 48.88) | |
| 0.26 (0.08, 0.80) | 0.19 (0.04, 0.82) | 0.68 (0.17, 2.81) | 0.23 (0.06, 0.93) | 0.89 (0.18, 4.41) | RT + TP + SQFZ | 1.22 (0.03, 49.90) | |
RT: radiotherapy; CCRT: concurrent chemoradiotherapy; DDP: cisplatin chemotherapy; DP: docetaxel plus cisplatin chemotherapy; TP: paclitaxel plus cisplatin chemotherapy; AD: Aidi; HQ: Huangqi; FFKS, Fufangkushen; KA: Kangai; KLT: Kanglaite; RSDT: Renshenduotang; SQFZ: Shenqifuzheng; SM: Shenmai; YDZ: Yadanzi; GRR: gastrointestinal reaction rate; -, not reported; The table data on the lower left of the gray bottom tables represents LRR, and the upper right GRR; bold font data represents a significant difference.